# Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

> **NCT04415008** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 61 (actual)

## Conditions studied

- CEBPA Double Mutation
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** HAD induction with intermediate dose cytarabine

## Key facts

- **NCT ID:** NCT04415008
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-01
- **Primary completion:** 2026-10-03
- **Final completion:** 2027-06-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04415008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04415008, "Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04415008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*